Search

Your search keyword '"Han, J.-Y."' showing total 32 results
Start Over Author "Han, J.-Y." Publisher wiley
32 results on '"Han, J.-Y."'

3. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients

Author

Yoo, S. H., primary, Kwon, J. H., additional, Nam, S. W., additional, Kim, H. Y., additional, Kim, C. W., additional, You, C. R., additional, Choi, S. W., additional, Cho, S. H., additional, Han, J.-Y., additional, Song, D. S., additional, Chang, U. I., additional, Yang, J. M., additional, Lee, H. L., additional, Lee, S. W., additional, Han, N. I., additional, Kim, S.-H., additional, Song, M. J., additional, Hwang, S., additional, Sung, P. S., additional, Jang, J. W., additional, Bae, S. H., additional, Choi, J. Y., additional, and Yoon, S. K., additional

Published
2018
Full Text
View/download PDF

13. Pharmacokinetics of Oltipraz and Its Major Metabolite (RM) in Patients With Liver Fibrosis or Cirrhosis: Relationship With Suppression of Circulating TGF-β1

Author

Kim, S G, primary, Kim, Y M, additional, Choi, Y H, additional, Lee, M G, additional, Choi, J Y, additional, Han, J Y, additional, Cho, S H, additional, Jang, J W, additional, Um, S H, additional, Chon, C Y, additional, Lee, D H, additional, Jang, J J, additional, Yu, E S, additional, and Lee, Y S, additional

Published
2010
Full Text
View/download PDF

27. Shallow donors in GaN

Author

Freitas, J. A., primary, Moore, W. J., additional, Shanabrook, B. V., additional, Braga, G. C. B., additional, Koleske, D. D., additional, Lee, S. K., additional, Park, S. S., additional, and Han, J. Y., additional

Published
2003
Full Text
View/download PDF

31. Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.

Author

Kim SG, Kim YM, Choi YH, Lee MG, Choi JY, Han JY, Cho SH, Jang JW, Um SH, Chon CY, Lee DH, Jang JJ, Yu ES, and Lee YS

Subjects
Administration, Oral, Adult, Antiviral Agents administration & dosage, Antiviral Agents pharmacology, Area Under Curve, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Half-Life, Humans, Liver Cirrhosis pathology, Male, Middle Aged, Pyrazines administration & dosage, Pyrazines pharmacology, Thiones, Thiophenes, Antiviral Agents pharmacokinetics, Liver Cirrhosis drug therapy, Pyrazines pharmacokinetics, Transforming Growth Factor beta1 metabolism
Abstract

Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylthio)H-pyrrolo[1,2-a]pyrazine (RM)) were evaluated after single-dose (30-90 mg) and multiple-dose (60 mg b.i.d. or 90 mg q.d. for 24 weeks) oral administration of oltipraz to patients with LF or LC. Oltipraz was safe and well tolerated in both studies. In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (C(max)), and terminal half-life (t(1/2)) of oltipraz as well as the AUC of its RM were dose dependent. Oltipraz was rapidly absorbed; the time to reach C(max) (T(max)) was 2-4 h. The conversion of oltipraz to RM was also rapid and substantial (AUC of RM from time 0 to the last measured concentration (AUC(last, RM))/AUC(last, oltipraz), 42-61%). In the multiple-dose study, the level of transforming growth factor-beta1 (TGF-beta1) (a blood fibrosis marker) was suppressed at steady-state plasma concentrations of approximately 20-60 ng/ml of oltipraz or of approximately 60-140 ng/ml of oltipraz plus RM. Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen.

Published
2010
Full Text
View/download PDF

32. Enrichment and detection of fetal erythroid cells from maternal peripheral blood using liquid culture.

Author

Han JY, Lee YH, Sin SD, Park JI, Kim IH, Je GH, and Rodgers GP

Subjects
DNA analysis, Erythrocyte Count, Erythropoietin pharmacology, Female, Fetal Hemoglobin analysis, Gestational Age, Humans, Karyotyping, Male, Polymerase Chain Reaction, Pregnancy, Y Chromosome, Blood Cells cytology, Cell Culture Techniques, Cell Separation methods, Erythroid Precursor Cells cytology, Fetus
Abstract

Isolating fetal cells from maternal blood for prenatal genetic analysis is the least invasive method currently being investigated. In order to enrich these fetal erythroid cells we employed a two-phase liquid culture system that supports the growth and differentiation of erythroid progenitor cells. Mononuclear cells were separated from ten maternal blood samples at 8-14(+3) weeks of gestation and cultured in the first phase. After 4-5 days, the non-adherent cells were harvested and recultured with erythropoietin for another 3-4 days. The mean number of total erythroid cells reached approximately 0.77x10(6)/ml with an average purity of 90.5%. Hb F stain disclosed fetal erythroid cells averaging approximately 5.7%, therefore the mean number of fetal erythroid cells isolated was 0.49x10(5)/ml. Female karyotypes were only observed while counting 5-66 metaphases. However, male DNA (SRY or DYZ1) was detected by PCR in 7/10 cases; in four of these cases and in one SRY-negative pregnancy the 46,XY karyotype was found by amniocentesis performed during the second trimester. This liquid culture system provided an enriched source of fetal cells without the need for more complicated separation or sorting procedures., (Copyright 2001 John Wiley & Sons, Ltd.)

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results